CN1860119A - 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物 - Google Patents

用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物 Download PDF

Info

Publication number
CN1860119A
CN1860119A CNA2004800280878A CN200480028087A CN1860119A CN 1860119 A CN1860119 A CN 1860119A CN A2004800280878 A CNA2004800280878 A CN A2004800280878A CN 200480028087 A CN200480028087 A CN 200480028087A CN 1860119 A CN1860119 A CN 1860119A
Authority
CN
China
Prior art keywords
compound
disease
patient
disorder
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800280878A
Other languages
English (en)
Chinese (zh)
Inventor
A·戈萨尔
仝威
S·K·乔哈里
S·兹拜达
M·A·维尔思
K·B·阿尔顿
J·E·帕特里克
C·D·博伊尔
A·史丹佛德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1860119A publication Critical patent/CN1860119A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2004800280878A 2003-07-31 2004-07-29 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物 Pending CN1860119A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49221803P 2003-07-31 2003-07-31
US60/492,218 2003-07-31

Publications (1)

Publication Number Publication Date
CN1860119A true CN1860119A (zh) 2006-11-08

Family

ID=34115611

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800280878A Pending CN1860119A (zh) 2003-07-31 2004-07-29 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物

Country Status (10)

Country Link
US (1) US7312223B2 (enExample)
EP (1) EP1648895B1 (enExample)
JP (1) JP2007500714A (enExample)
CN (1) CN1860119A (enExample)
AT (1) ATE363483T1 (enExample)
CA (1) CA2533715A1 (enExample)
DE (1) DE602004006756T2 (enExample)
ES (1) ES2284056T3 (enExample)
MX (1) MXPA06001195A (enExample)
WO (1) WO2005012303A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106770618A (zh) * 2015-11-20 2017-05-31 中国康复研究中心 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
WO2003101992A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
EP1786428B1 (en) * 2004-08-17 2012-05-16 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
KR20090087795A (ko) * 2008-02-13 2009-08-18 한양대학교 산학협력단 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
US20100261737A1 (en) * 2009-04-10 2010-10-14 Medtronic Vascular, Inc. Method of Treating Erectile Dysfunction
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2013054153A1 (en) 2011-10-11 2013-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Nutlin compounds for use in he treatment of pulmonary hypertension

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5409934A (en) * 1990-12-21 1995-04-25 Smith; David G. Xanthine derivatives
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
CN1118600A (zh) * 1993-02-26 1996-03-13 先灵公司 2-苄基-多环鸟嘌呤衍生物以及制备它们的方法
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
WO2003101992A1 (en) 2002-05-31 2003-12-11 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
AR040233A1 (es) 2002-05-31 2005-03-23 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106770618A (zh) * 2015-11-20 2017-05-31 中国康复研究中心 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法

Also Published As

Publication number Publication date
HK1082739A1 (en) 2006-06-16
WO2005012303A1 (en) 2005-02-10
EP1648895B1 (en) 2007-05-30
CA2533715A1 (en) 2005-02-10
ATE363483T1 (de) 2007-06-15
US20050026939A1 (en) 2005-02-03
DE602004006756D1 (de) 2007-07-12
MXPA06001195A (es) 2006-04-11
DE602004006756T2 (de) 2008-01-24
JP2007500714A (ja) 2007-01-18
ES2284056T3 (es) 2007-11-01
EP1648895A1 (en) 2006-04-26
US7312223B2 (en) 2007-12-25

Similar Documents

Publication Publication Date Title
CN1095841C (zh) 化合物
DE60018216T2 (de) Kondensierte purinderivate
CN1121917A (zh) 3-苯基吡咯烷衍生物
CN101056879A (zh) 作为a3和a1腺苷受体激动剂的嘌呤衍生物
CN1483034A (zh) 吲哚衍生物及其作为5-ht2b和5-ht2c受体配体的应用
CN1232463A (zh) 吡唑并吡啶基哒嗪酮衍生物及其制备方法
CN1630636A (zh) 二氢吲哚衍生物及其作为5－ht2受体配体的用途
CN1720232A (zh) 汉防己碱和汉防己碱化合物,合成和应用
EP4332102A1 (en) Isoquinolone compound and use thereof
CN1135485A (zh) 2，9-二取代的嘌呤-6-酮类化合物
CN1280292C (zh) 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
CN1860119A (zh) 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物
CN1018644B (zh) 二唑-烷基-嘌呤衍生物的制备方法
CN1097459C (zh) 用作磷酸二酯酶iv抑制剂的二氮杂䓬并吲哚
CN1656097A (zh) 黄嘌呤磷酸二酯酶v抑制剂多晶型物
CN1756757A (zh) 吡咯并咪唑衍生物、其制备、包含它们的药物组合物及其作为向精神剂的应用
DE602004012146T2 (de) Pyrazolopyrimidine
CN101065382A (zh) 用于治疗炎性疾病的被取代的蝶啶类
EP2253632A1 (en) Pyrazolopyramidinone derivatives, their preparation and their use
JP2006514651A (ja) １−アルキル−３−アミノインダゾール
CN101052393A (zh) 氮杂双环己烷的新型多晶型物
JP7515510B2 (ja) （３ｒ，４ｒ）－１－ベンジル－ｎ，４－ジメチルピペリジン－３－アミンまたはその塩の製造方法、およびそれを使用したトファシチニブの製造方法
CN1606557A (zh) 经氘代的吡唑嘧啶酮以及包含该化合物的药物组合物
CN1141773A (zh) 含6-氧代-氮杂䓬吲哚的药物的制备方法
CN1139588C (zh) 新的氟化咪唑啉苯并二噁烷,其制备及其治疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20061108